{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.58","value":"-4.3"},{"groupId":"OG001","spread":"18.21","value":"4.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"110"}],"units":"Participants"}],"description":"The EQ-5D questionnaire is a brief, generic health-related quality of life assessment (HRQOL) that can also be used to incorporate participant preferences into health economic evaluations. The EQ-5D questionnaire assesses HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a visual analog scale with response options ranging from 0 (worst imaginable health) to 100 (best imaginable health).","dispersionType":"Standard Deviation","groups":[{"description":"Participants received ibrutinib 420 milligram (mg) (3 \\* 140 mg capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles ibrutinib alone was administered until disease progression or unacceptable toxicity.","id":"OG000","title":"Ibrutinib+BR"},{"description":"Participants received placebo (3 capsules) orally once daily starting on Cycle 1 Day 2 for a maximum of 6 cycles (each cycle of 28 days except Cycle 1 which was of 29 days) along with BR. After 6 cycles placebo alone was administered until disease progression or unacceptable toxicity.","id":"OG001","title":"Placebo+BR"}],"paramType":"MEAN","populationDescription":"ITT population included all participants randomized into the study regardless of treatment actually received. Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this endpoint.","reportingStatus":"POSTED","timeFrame":"Baseline to EOT (up to 2 years)","title":"Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Visual Analog Scale at End of Treatment","type":"SECONDARY","unitOfMeasure":"Units on a scale"}